01 Near-Patient Molecular TB TestingThe tuberculosis diagnostics market analysis indicates that point-of-care molecular testing platforms are gaining traction as healthcare providers seek faster TB diagnosis in decentralized settings. Cartridge-based nucleic acid amplification tests (NAATs) detect Mycobacterium tuberculosis DNA and identify selected drug-resistance markers, such as mutations associated with rifampicin resistance, through automated sample processing and molecular analysis. This development is supporting the deployment of compact diagnostic systems in community clinics and peripheral healthcare facilities, reducing reliance on centralized laboratories and enabling earlier treatment decisions.
02 Expanded Drug-Resistance DetectionRising concern over multidrug-resistant and extensively drug-resistant tuberculosis is increasing the need for diagnostic platforms that identify multiple resistance markers. Advanced molecular assays and targeted sequencing technologies enable laboratories to assess resistance to a broader range of anti-TB drugs. This development is encouraging diagnostic manufacturers to expand drug-resistance testing capabilities, supporting more informed treatment selection and improved management of resistant TB cases.
01 Rising Need for Drug-Resistance TestingThe rising prevalence of drug-resistant tuberculosis increases the need for tests that identify resistance to commonly used TB medicines. Accurate resistance detection helps healthcare providers select effective treatment regimens and reduce delays in appropriate care. For example, GeneXpert MTB/RIF testing detects tuberculosis bacteria and identifies resistance to rifampicin, supporting early treatment decisions. This growing clinical requirement increases demand for molecular diagnostic platforms, drug-susceptibility tests, and specialized laboratory supplies.
02 Impact Analysis of Key Drivers in TB Diagnostics MarketDriversMarket ImpactHigh Burden of Undiagnosed TB CasesThe large number of people with undiagnosed tuberculosis creates demand for expanded diagnostic coverage and routine testing. National health programmes and healthcare providers require greater testing capacity to identify missed cases, increasing demand for sputum testing, laboratory services, and diagnostic consumables.Rising Need for Drug-Resistance TestingThe prevalence of multidrug-resistant and rifampicin-resistant TB increases the need for tests that identify resistance to specific medicines. Healthcare providers require drug-susceptibility testing to select effective treatment regimens, supporting demand for molecular and culture-based diagnostic tests.Increasing TB Screening Among High-Risk GroupsPeople living with HIV, household contacts of TB patients, and individuals with conditions such as diabetes require targeted screening and diagnostic evaluation. These screening needs expand testing volumes across hospitals, community health centres, and specialized diagnostic laboratories.Expansion of National TB Elimination ProgrammesGovernment-led TB control initiatives increase the procurement of diagnostic equipment, laboratory supplies, and testing services. Public-sector investment and free diagnostic programmes support wider access to TB testing and create institutional demand for diagnostic products.Growing Need for Laboratory Testing CapacityRising diagnostic workloads increase the need for additional laboratory facilities, testing equipment, trained personnel, and reliable consumable supplies. Investments in laboratory infrastructure strengthen testing capacity and support demand for reagents, culture media, and diagnostic instruments.
May 2026 QIAGEN announced plans to advance its QuantiFERON latent TB testing portfolio with a fully automated Sample-to-Insight workflow and an AI-enabled TB progression risk-stratification tool, supported by a new automation partnership with Inpeco.
March 2026 The World Health Organization issued its first recommendations for near-point-of-care molecular TB tests, tongue-swab specimens, and sputum pooling, expanding the range of diagnostic technologies suitable for decentralized TB detection.
July 2025 The NIIDAN-TB pilot project was launched in Nagpur with AI-assisted mobile TB screening vans and a molecular diagnostic laboratory for drug-resistance testing, expanding advanced tuberculosis detection infrastructure and high-risk population screening.
May 2025 India's TB diagnostics ecosystem continued expanding decentralized molecular testing capacity through portable rapid-testing platforms and broader deployment strategies aimed at moving diagnosis closer to primary and community healthcare settings. The expanding pipeline included biomarker-based point-of-care and near-point-of-care diagnostic products.